BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 19, 2009
 |  BC Week In Review  |  Company News  |  Deals

Medicines Co., Targanta deal

The Medicines Co. plans to acquire Targanta in a tender offer of $2 per share, or about $42 million in cash. The price is a 72% premium to Targanta's close of $1.16 on Jan. 12, before the deal was announced. Targanta shareholders will be eligible for up to $4.55 per share, or about $95.5 million, in regulatory and sales milestones for lead compound oritavancin. The...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >